Want to see TSE:MRVL full AI Analyst Report?
Top Page
Marvel Biosciences Corp
(MRVL)
Select Model
Select Model
Rating:46Neutral
Price Target:
C$0.15
▲(1.33% Upside)
Action:Reiterated
Date:06/20/26
The score is held down primarily by weak financial performance (no revenue, persistent losses, negative equity, and negative free cash flow indicating ongoing funding/dilution risk). Technical indicators are comparatively neutral-to-slightly constructive, but valuation remains challenged due to negative earnings and no stated dividend yield.
Positive Factors
Improving Net Loss
The reduced annual loss indicates some progress in controlling expenses or limiting deterioration. However, the improvement is not yet sufficient to establish a sustainable earnings profile because the company still has no revenue and remains loss-making.
Negative Factors
No Revenue Base
The absence of revenue is a fundamental commercialization risk for a biotechnology company. Without an established revenue stream, operating costs cannot be self-funded, making long-term sustainability dependent on successful development, partnerships, or external capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving Net Loss
The reduced annual loss indicates some progress in controlling expenses or limiting deterioration. However, the improvement is not yet sufficient to establish a sustainable earnings profile because the company still has no revenue and remains loss-making.
Read all positive factors
Marvel Biosciences Corp (MRVL) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$8.82M
Dividend YieldN/A
Average Volume (3M)50.55K
Price to Earnings (P/E)―
Beta (1Y)-0.09
Revenue GrowthN/A
EPS Growth25.70%
CountryCA
Employees5
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding63,028,290
10 Day Avg. Volume44,784
30 Day Avg. Volume50,555
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-2.07
Price to Sales (P/S)0.00
P/FCF Ratio-7.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Marvel Biosciences Corp Business Overview & Revenue Model
Company Description
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company’s lead compound MB-204, a novel fluorinated derivative of istradefylline...
Marvel Biosciences Corp Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Jul 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -385.42K | -547.37K | -302.02K | -887.52K | -1.38M | -613.10K |
| EBITDA | -1.92M | -1.94M | -1.54M | -2.25M | -2.55M | -1.25M |
| Net Income | -1.39M | -2.21M | -1.65K | -2.29M | -2.55M | -3.04M |
Balance Sheet | ||||||
| Total Assets | 471.73K | 326.71K | 491.31K | 672.39K | 913.54K | 2.47M |
| Cash, Cash Equivalents and Short-Term Investments | 434.80K | 128.85K | 345.77K | 556.62K | 593.21K | 2.39M |
| Total Debt | 1.40M | 2.31M | 1.71M | 1.00M | 0.00 | 0.00 |
| Total Liabilities | 3.21M | 4.33M | 3.32M | 2.39M | 718.00K | 112.48K |
| Stockholders Equity | -2.73M | -4.01M | -2.83M | -1.72M | 195.54K | 2.36M |
Cash Flow | ||||||
| Free Cash Flow | -778.84K | -1.15M | -1.18M | -1.33M | -2.19M | -1.37M |
| Operating Cash Flow | -778.84K | -1.15M | -1.18M | -1.33M | -2.19M | -1.37M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 381.57K |
| Financing Cash Flow | 824.62K | 933.41K | 968.64K | 1.30M | 394.00K | 3.16M |
Marvel Biosciences Corp Technical Analysis
Neutral
0.15
Price Trends
0.16
Negative
0.16
Negative
0.16
Negative
Market Momentum
>-0.01
Positive
47.80
Neutral
54.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MRVL, the sentiment is Neutral. The current price of 0.15 is below the 20-day moving average (MA) of 0.15, below the 50-day MA of 0.16, and below the 200-day MA of 0.16, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 47.80 is Neutral, neither overbought nor oversold. The STOCH value of 54.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:MRVL.
Marvel Biosciences Corp Peers Comparison
UnderperformOutperform
Sector (55)
TSE:MRVL
Marvel Biosciences Corp
0.15
-0.10
-40.00%
TSE:BETR
BetterLife Pharma
0.34
0.26
300.00%
TSE:DRUG
Bright Minds Biosciences
88.40
26.59
43.02%
TSE:MYND
MYND Life Sciences
0.07
0.00
0.00%
Marvel Biosciences Corp Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Marvel Biosciences Extends Private Placement Access to Quebec Investors
Positive
Aug 19, 2026
Marvel Biosciences Corp. is a Calgary-based pre-clinical biotechnology company that redevelops existing, off-patent drugs into new synthetic derivatives aimed at treating neurological and non-neurological diseases. By focusing on targets such as t...
Business Operations and Strategy
Marvel Biosciences’ MB-204 Shows Robust Efficacy in Fragile X Preclinical Study
Positive
Aug 5, 2026
Marvel Biosciences announced positive preclinical results showing its lead drug candidate MB-204 reversed behavioural and cognitive deficits in a Fragile X mouse model in a study run through the FRAXA Drug Validation Initiative. The compound produ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.